Tissue plasminogen activator (tPA) has a critical role in fibrinolysis, converting plasminogen into active protease plasmin. Because intravenous tPA has only limited effectiveness as acute stroke therapy, enhancement of endogenous tPA represents a potential alternative to stroke treatment. Adenoviral-mediated gene transfer was used to enhance production of tPA in bovine brain capillary endothelial cells (BEC). Antigen and activity levels of tPA and plasminogen activator inhibitor-1 (PAI-1) in media from BEC infected with AdCMVtPA were analyzed. Conditioned media were analyzed for thrombomodulin, the integral membrane antithrombotic molecule that co-activates protein C. BEC infected with AdCMVtPA demonstrated enhanced expression of tPA antigen (40.2 ±0.4 ng/mL vs 1.1 ±1.5 ng/mL [p<0.001] and 0.3 ±0.5 ng/mL [p<0.0001 ], respectively) and increased tPA enzymatic activity (27.4 ±5.7 IU/mL vs 8.3 ±1.7 IU/mL [p<0.05] and 13.3 ±3.2 IU/mL [p<0.05], respectively) compared to BEC infected with the control adenovirus (AdI327) or uninfected BEC. There was a moderate increase in PAI-1 protein 4 days after transfection with AdCMVtPA, and the integral membrane protein throm bomodulin was released into media by transfected BEC. These results demonstrate that aden oviral-mediated delivery in vitro of the human tPA gene resulted in high levels of expression of tPA in BEC. Transient overexpression of tPA by gene transfer might be a useful strategy to protect against thrombotic occlusion during the period of risk of acute stroke.
Get full access to this article
View all access options for this article.
References
1.
Wiman B.: Plasminogen activator inhibitor 1 (PAI-1) in plasma: Its role in thrombotic disease. Thromb Haemost74:71-76, 1995.
2.
Levin EG, del Zoppo GJ: Localization of tissue plasminogen activator in endothelium of a limited number of vessels. Am J Pathol144:855-861, 1994.
3.
Kollros PR, Konkle BA, Ambarian AP, et al: Plasminogen activator inhibitor-1 expression by brain microvessel endothelial cells is inhibited by elevated glucose. J Neurochem63:903-909, 1994.
4.
Shatos MA, Orfeo T., Doherty JM, et al: α-Thrombin stimulates urokinase production and DNA synthesis in cultured human cerebral microvascular endothelial cells. Arterioscler Thromb Vasc Biol15:903-911, 1995.
5.
The National Institute of Neurological Disorders and Stroke t-PA Stroke Study Group: Tissue plasminogen activator in acute ischemic stroke . N Engl J Med333:1581-1587, 1995 .
6.
del Zoppo GJ , Higashida RT, Furlan AJ, et al: PROACT; a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. Stroke29:4-11, 1998.
7.
Tran ND, Schreiber SS, Fisher M.: Astrocyte regulation of endothelial tissue plasminogen activator in a blood-brain barrier model. J Cereb Blood Flow Metab18:1316-1324, 1998.
8.
Le Gal La Salle G., Pobert JJ, Berrard S., et al: An adenovirus vector for gene transfer into neurons and glia in the brain. Science259:988-990, 1993.
9.
Smith GM, Romero MI: Adenoviral-mediated gene transfer to enhance neuronal survival, growth and regeneration. J Neuroscience Res55:147-157, 1999.
10.
Herz J., Gerard RD: Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice. Proc Nat Acad Sci USA90:2812-2816, 1993 .
11.
Ooboshi H., Welsh MJ, Rios D., et al: Adenovirus-mediated gene transfer in vivo to cerebral blood vessels and perivascular tissue. Circ Res77:7-13, 1995.
12.
Spady DK, Cuthbert JA, Willard MN, et al: Adenovirus-mediated transfer of a gene encoding cholesterol 7-α hydroxylase into hamsters increases hepatic enzyme activity and reduces serum total and LDL cholesterol. Circulation Suppl 90:I-90, 1994.
13.
Ohno T., Gordon D., San H., et al: Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science265:781-784, 1994.
14.
Christenson SD, Lake KD, Ooboshi H., et al: Adenovirus-mediated gene transfer in vivo to cerebral blood vessels and perivascular tissue in mice. Stroke29:1411-1416, 1998 .
Ooboshi H., Rios CD, Heistad DD: Novel methods for adenoviral-mediated gene transfer to blood vessels in vivo . Mol Cell Biochem172:37-46, 1997.
17.
Weihl C., Macdonald RL, Stoodley M., et al: Gene therapy for cerebrovascular disease. Neurosurgery44:239-252, 1999.
18.
Carmeliet P. , Stassen J-M., Van Vlaenderen I., et al: Adenovirus-mediated transfer of tissue-type plasminogen activator augments thrombolysis in tissuetype plasminogen activator-deficient and plasminogen activator inhibitor-1-overexpressing mice. Blood90:1527-1534, 1997 .
19.
Madison EL, Goldsmith EJ, Gerard RD, et al: Amino acid residues that affect interaction of tissue-type plasminogen activator with plasminogen inhibitor 1. Proc Natl Acad Sci USA87:3530-3537, 1990.
Gomez-Foix AM, Coats WS, Baque S., et al: Adenovirus-mediated transfer of the muscle glycogen phosphorylase gene into hepatocytes confers altered regulation of glycogen metabolism. J Biol Chem267:25129-25134, 1992.
22.
Stins MF, Presadarao NV, Ibric L., et al: Binding characteristics of S fimbriated Escherichia coli to isolated brain microvascular endothelial cells. Am J Pathol145:1228-1236, 1994.
23.
Tran ND, Wong Vly, Bready J., et al: Regulation of brain capillary endothelial thrombomodulin mRNA expression. Stroke27:2304-2311, 1996 .
24.
Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature227:680-685, 1970.
25.
Dittman WA, Majerus PW: Structure and function of thrombomodulin: A natural anticoagulant . Blood75:329-336, 1990.
26.
Shatos MA, Doherty JM, Penar PL, et al: Suppression of plasminogen activator inhibitor-1 release from human cerebral endothelium by plasminogen activators. Circulation94:636-642, 1996.
27.
Esmon CT: The regulation of natural anticoagulant pathways. Science235:1348-1352, 1987.
28.
Lentz SR, Sadler JE: Structure-function relationships of the thrombin-thrombomodulin interaction . Haemostasis23(suppl 1):183-193, 1993.
29.
Key NS, Vercellotti GM, Winkelmann JC, et al: Infection of vascular endothelial cells with herpes simplex virus enhances tissue factor activity and reduces thrombomodulin expression . Proc Natl Acad Sci USA7:7095-7099, 1990 .
30.
Boffa MC, Karochkine M., Berard M.: Plasma thrombomodulin as a marker of endothelium damage. Nouv Rev Fr Hematol33:529-535, 1991.
31.
Sugawara Y. , Sakada Y., Minowada S., et al: Adenovirus-mediated transfer of tissue-type plasminogen activator gene to human endothelial cells . Surgery122:91-100, 1997.
32.
Dichek DA, Nussbaum O., Degen Sjf, et al: Enhancement of the fibrinolytic activity of sheep endothelial cells by retroviral vector-mediated gene transfer. Blood77:533-541, 1991.
33.
Dichek DA, Anderson J., Kelly AB, et al: Enhanced in vivo antithrombotic effects of endothelial cells expressing recombinant plasminogen activators transduced with retroviral vectors . Circulation93:301-309, 1996.
34.
Huber TS, Welling TH, Sarkar R., et al: Effects of retroviral-mediated tissue plasminogen activator gene transfer and expression on adherence and proliferation of canine endothelial cells seeded onto expanded polytetrafluoroethylene. J Vasc Surg22:795-803, 1995.
35.
Podrazik RM , Whitehill TA, Ekhterae D., et al: High-level expression of recombinant human tPA in cultivated canine endothelial cells under varying conditions of retroviral gene transfer. Ann Surg216:446-453, 1992.
36.
Yu H., Wang Y., Eton D., et al: Retroviral vector-mediated transfer and expression of human tissue plasminogen activator cDNA in bovine brain endothelial cells. Neurosurgery45:962-970, 1999.
37.
Ragot T., Vincent N., Chafey P., et al: Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice. Nature361:647-650, 1993.
38.
Kanegae Y., Makimura M., Saito I.: A simple and efficient method for purification of infectious recombinant adenovirus . Jpn J Med Sci Biol47:157-166, 1994.
39.
Tripathy SK , Black HB, Goldwasser E., et al: Immune response to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nature Med2:545-550, 1996.
40.
Morelli AE, Larregina AT, Smith-Arica J., et al: Neuronal and glial cell-type specific promoters within adenovirus recombinants restrict expression of apoptosis-inducing molecule Fas ligand to predetermined brain cell types and abolish liver toxicity. J Gen Virol80:571-583, 1999.
41.
Ridet JL, Corti O., Pencalet P., et al: Toward autologous ex vivo gene therapy for the central neuron system with adult human astrocytes. Hum Gene Ther10:271-280, 1999.
42.
Yeh P., Perricaudet M.: Advances in adenoviral vectors from genetic engineering to their biology . Faseb J11:615-623, 1997.
43.
Christ M., Lusky M., Stoekel F., et al: Gene therapy with recombinant adenovirus vectors: Evaluation of the host immune response. Immunol Letters57 :19-25, 1997.
44.
McClane SJ, Hamilton TE, DeMatteo RP, et al: Effect of adenoviral early genes and the host immune system on in vivo pancreatic gene transfer in the mouse pancreas. Pancreas15:236-245, 1997.
45.
Peltekian E. , Parrish E., Bouchard C., et al: Adenovirus-mediated gene transfer to the brain: methodological assessment. J Neurosc Methods71:77-84, 1997.
46.
Draghia R., Caillaud C., Manicom R., et al: Gene delivery into the central nervous system by nasal instillation in rats. Gene Therapy2:418-423, 1995.
47.
Lawrence MS , McLaughlin JR, Sun GH, et al: Herpes simplex viral vectors expressing Bcl-2 are neuroprotective when delivered after a stroke. J Cereb Blood Flow Metab17:740-744, 1997.
